The group believes that being able to track ctDNA changes down to the lowest possible levels may be necessary for liquid biopsy to monitor treatment in early-stage cancers.
The partners will work together on a US commercialization strategy for Genetic Technologies' line of existing and future polygenic risk tests.
The partners inked a licensing deal to market and distribute TGen's DeepChek-TB as a compact, portable, and affordable diagnostic model for physician use.
An affiliation with City of Hope, the advent of Illumina NovaSeq, and the availability of HPC flash storage have changed the nature of high-performance computing at TGen.
A brief recap of Genetics/Genomics news the week of Dec 14, 2018: AstraZeneca, NeoGenomics, Fluidigm, Luminex, Petco Foundation, and SQI Diagnostics
The institutes will lead a consortium of researchers investigating the molecular underpinnings of diabetic retinopathy, a key cause of blindness.
Investigators are studying samples from a group of 100 patients to try to lock down patterns in circulating tumor DNA that can be used to validate monitoring methods for the clinic.
The project aims to use circulating tumor DNA to monitor drug response and resistance in metastatic melanoma patients in order to guide treatment decisions.
Using meat and clinical samples collected prospectively over a year, researchers found evidence for poultry-to-human transmission of Escherichia coli sequence type 131.
The partners will particularly examine cell-free and exosomal RNAs as potential biomarkers for early-stage pancreatic cancer diagnosis in patients.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.